Navigation Links
ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Date:7/29/2008

LEUVEN, Belgium, July 30 /PRNewswire-FirstCall/ --

- Shares Acquired From Biggar Limited

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, today announces that a group of private investors based in Belgium have together acquired an 8% stake in the Company. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics largest shareholder. Biggar now holds a 9.8% stake in ThromboGenics following this transaction, and has informed the company that it intends to remain an important shareholder in ThromboGenics for the long term.

This transaction was managed by Petercam.

Prof. Desire Collen, Chairman and CEO of ThromboGenics, commenting on today's announcement, said: "We are very pleased that we have been able to attract such a group of high net worth individuals to become shareholders in ThromboGenics, particularly given their long term commitment to the Company. We are confident that we will be able to generate significant value for all our shareholders over the next several years based on the exciting prospects for microplasmin in the treatment of back of the eye disease, our other pipeline products, including TB-402 for deep vein thrombosis, as well as the significant potential that we see for TB-403 in the treatment of cancer, which was recently licensed to Roche."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. ThromboGenics N.V. - Business Update
3. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
4. ThromboGenics Announces 2007 Full Year Results
5. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
8. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
9. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
10. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...RDAM, November 30 Elsevi...edical and technical products and services,today ...ensive biomedical,database which holds over 20 mil...peer reviewed journals. , Embase has long...dical,and pharmaceutical insights. Now, new develo...
(Date:11/27/2009)...-FirstCall/ -- Stallergenes has been,granted Europ...nd children,through a Mutual Recognition Procedure...been marketed, was the reference Member state. ,...elgium, Bulgaria, Cyprus, the,Czech Republic, Esto...aly,Latvia, Lithuania, Luxembourg, Malta, the Net...
(Date:11/25/2009)... -- Biotech firm Replikins Ltd., which has analyze...mic through the prediction, outbreak, and progress...test biochemical analysis of the virus. The new da...u") virus has dropped from its peak of 3.7 (s.d. 4...ing of 2009 to resting non-epidemic levels this we...
(Date:11/25/2009)...swire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a lead...today that it executed,a joint venture (JV) agreem...gy Co., Ltd. (Sinovac Dalian). The JV will researc...ccines. Sinovac will contribute its expertise,and ...-class vaccines; the,other party will bring its la...
Breaking Biology Technology:Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3
...r 5 SALVAT announced today the,submission of the ...(R),(Ciprofloxacin 0.2% Otic Solution in Single Do...n April 6, 2006, the FDA requested additional,data...trols (CMC)., SALVAT expects the FDA to classify ...nder which the FDA will seek to complete its revie...
...5 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) tod...it Suisse Health Care Conference on Wednesday, Nov...cific Time). Interested parties,may access a live ...tp://www.onyx-pharm.com/wt/page/event_calendar , ... early in order to,register and download any neces...
...re-FirstCall/ - Dr. Brad Thompson, President,and C...ONC, NASDAQ:ONCY),will host a conference call and .... MT (1:00 p.m. ET) to update investors on clinica...ients with bone and soft tissue sarcomas,metastati...sented November,6, 2008 at the Chemotherapy Founda...
Other Biology Technology:SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R) 2Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call 2
(Date:11/25/2009)...er 11, firefighters, police officers and ambulance...orld Trade Center complex. They battled to save pe... survivors, tackled fires and evacuated as many pe...stimated 17,000 people. And making their jobs even...ightened workers and their relatives jammed mobile...
(Date:11/25/2009)..., CAWhen you eat may be just as vital to your heal...Institute for Biological Studies. Their experiment...g of thousands of genes in the liverthe body,s met...ntake and not by the body,s circadian clock as con...ermines the activity of a large number of genes co...
(Date:11/24/2009)...t keep weakened and flabby arteries from collapsin..., those stents are no longer needed -- once the ar...Previously, doctors had no choice but to leave the... University,s Department of Biomedical Engineering... that carries drugs where they,re needed, then dis...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Hormone clue to root growth 9134 1Hormone clue to root growth 9134 2EnVivo to Share Results of its EVP 6124 Phase Ib IIa Trial at The International Conference on Alzheimers Disease 50909 1EnVivo to Share Results of its EVP 6124 Phase Ib IIa Trial at The International Conference on Alzheimers Disease 50909 2Johnson 26 Johnson to Host Analyst Conference Call on Second Quarter Results 50905 1
...ner gone" Thats the mystery The Academy of Natural...d the outcome will shed light on the environmental...rnot easy to spot at less than two inches longonce...ng small streams in Southeastern Pennsylvania. The...ssify the fish as endangered. Now, the Academy is ...
...f proteins, ribosomes and membranes inside a livin...ructural content of proteins by as much as 25 perc...y and the University of Houston (UH). The study is...wded environment inside a living cell affects prot...xpected crowding to affect proteins in the unfolde...
...e discovered a new class of hydrogen storage mater...n of energy much more efficient and affordable t...ellave S. Shivaram and Adam B. Phillips, the U.Va....resent their finding at 8 p.m., Monday, Nov. 12, a...in a Hydrogen Economy at the Omni Hotel in Richmon...
Other Biology News:Tiny fish can yield big clues to Delaware River health 2Proteins pack tighter in crowded native state 2Proteins pack tighter in crowded native state 3Scientists discover record-breaking hydrogen storage materials for use in fuel cells 2
Uniform 13C, 15N, Labeling of Peptides and Proteins new from rPeptide, LLC
SYBR Green I Nucleic Acid Gel Stain from Roche Applied Science
Mouse Anti-Human PRDM2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Rabbit Anti-Human S14G-Humanin Polyclonal Antibody, Unconjugated from Cosmo Bio Co., Ltd.
Biology Products: